These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16219569)

  • 1. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study.
    Langer C; Lengfelder E; Thiele J; Kvasnicka HM; Pahl HL; Beneke H; Schauer S; Gisslinger H; Griesshammer M
    Haematologica; 2005 Oct; 90(10):1333-8. PubMed ID: 16219569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
    Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
    Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon for the treatment of high-risk essential thrombocythemia.
    Mesa R
    Haematologica; 2005 Oct; 90(10):1298B. PubMed ID: 16219553
    [No Abstract]   [Full Text] [Related]  

  • 4. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
    Alvarado Y; Cortes J; Verstovsek S; Thomas D; Faderl S; Estrov Z; Kantarjian H; Giles FJ
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):81-6. PubMed ID: 12497210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
    Beauverd Y; Radia D; Cargo C; Knapper S; Drummond M; Pillai A; Harrison C; Robinson S
    Haematologica; 2016 May; 101(5):e182-4. PubMed ID: 26819057
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC).
    Sacchi S; Vinci G; Gugliotta L; Rupoli S; Gargantini L; Martinelli V; Baravelli S; Lazzarino M; Finazzi G
    Haematologica; 2000 May; 85(5):492-5. PubMed ID: 10800165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA;
    Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.
    Homoncik M; Ferlitsch A; Ferenci P; Formann E; Jilma B; Gangl A; Panzer S; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2005 Jan; 21(1):49-55. PubMed ID: 15644045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
    Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
    Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential thrombocythaemia treatment options: addressing patient-specific needs.
    Birgegård G
    Eur J Haematol Suppl; 2007 Oct; (68):27-31. PubMed ID: 17727563
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
    Tsantes AE; Nikolopoulos GK; Tsirigotis P; Zoi K; Zomas A; Kapsimali V; Kopterides P; Chondropoulos S; Dervenoulas J; Mantzios G
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):457-62. PubMed ID: 21836466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Essential thrombocythemia. Apropos a case of cerebrovascular stroke].
    Oliveira AS; Miranda MP; Duarte PC; Sarmento JN
    Acta Med Port; 1993 Oct; 6(10):461-5. PubMed ID: 8285117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
    Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
    Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
    Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alpha-2b in the long-term treatment of essential thrombocythemia.
    Sacchi S; Tabilio A; Leoni P; Riccardi A; Vecchi A; Messora C; Falzetti F; Rupoli S; Ucci G; Martelli MF
    Ann Hematol; 1991 Oct; 63(4):206-9. PubMed ID: 1932299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia.
    Kasparu H; Bernhart M; Krieger O; Lutz D
    Eur J Haematol; 1992 Jan; 48(1):33-6. PubMed ID: 1730277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indications for lowering platelet numbers in essential thrombocythemia.
    Barbui T
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia.
    Middelhoff G; Boll I
    Ann Hematol; 1992 May; 64(5):207-9. PubMed ID: 1623054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.